Fisher & Paykel Healthcare (ASX:FPH) share price higher on half year results

Here’s how this healthcare share is performing…
The post Fisher & Paykel Healthcare (ASX:FPH) share price higher on half year results appeared first on The Motley Fool Australia. –

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is on the move on Thursday morning.

At the time of writing, the medical device company’s shares are up 2% to $31.50.

Why is the Fisher & Paykel Healthcare share price rising?

Investors have been bidding the Fisher & Paykel Healthcare share price following the release of its half year results. Here’s a summary of how it performed during the six months ended 30 September:

Operating revenue was down 1% (up 2% in constant currency) to NZ$900 million
Hospital operating revenue down 2% to NZ$670.2 million
Homecare revenue up 0.3% to NZ$226.9 million
Net profit after tax down 2% (1% in constant currency) to NZ$222 million
Interim dividend increased 6% to 17 NZ cents per share

What happened during the half?

During the first half of FY 2022, Fisher & Paykel Healthcare reported a 1% decline in operating revenue to NZ$900 million and a 2% reduction in net profit after tax to NZ$222 million.

The main drag on the company’s performance was its Hospital product group, which includes humidification products used in respiratory, acute and surgical care. Segment revenue fell 2% after cycling the surge in demand for its respiratory products during the prior corresponding period at the height of pandemic.

Within the segment, consumables revenue grew 8% in constant currency and reached 67% of segment revenue. The remaining 33% of revenue was from the sale of hardware.

The Homecare product group, which includes products used in the treatment of obstructive sleep apnoea (OSA) and respiratory support in the home, delivered a modest 0.3% increase in revenue to NZ$227 million.

Pleasingly, despite contending with elevated freight costs, Fisher & Paykel Healthcare was able to deliver a 135 basis point increase in its gross margin to 63.1%.


Fisher & Paykel Healthcare’s Managing Director and CEO, Lewis Gradon, continued to warn that the second half will be tough. This could be what is weighing on the Fisher & Paykel Healthcare share price today.

He said: “We have not changed our view on outlook for the remainder of the financial year since we last provided an update on the 18th of August. For the second half, we expect our Hospital hardware sales will continue to be impacted by COVID19-related hospital admissions. However, as we said in our August trading update, many countries have already boosted their hospital treatment capacity, so we do not expect Hospital hardware revenue to continue at an elevated level for the rest of the year.”

Mr Gradon also warned that demand for consumables is uncertain due to a number of factors.

He explained: “In our Hospital product group, consumables volume is likely to be impacted by a number of different factors. Those include the ongoing COVID-19 hospitalisations around the world, the severity of the flu season during the Northern Hemisphere winter, and the ability of hospitals to return to their preCOVID-19 rates for surgeries.”

“Our second half last year corresponded to peak COVID-19 hospitalisations in North America and most European countries. In the absence of further comparable hospitalisation surges around the world, we would expect our consumables revenue for the second half of this financial year to be lower than the second half last year,” Mr Gradon added.

Unfortunately, the Homecare segment is also facing challenges of its own.

The CEO explained: “In our Homecare product group, growth in OSA masks is dependent on new patient diagnosis rates, which may continue to be impacted by COVID-19 and the supply of treatment hardware. We continue to expect new patient diagnoses to be at or above FY21 rates for the second half of the 2022 financial year.”

The post Fisher & Paykel Healthcare (ASX:FPH) share price higher on half year results appeared first on The Motley Fool Australia.

Should you invest $1,000 in Fisher & Paykel Healthcare right now?

Before you consider Fisher & Paykel Healthcare, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Fisher & Paykel Healthcare wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

November hasn’t been a great month so far for the IAG (ASX:IAG) share price

How do you value the Flight Centre (ASX:FLT) share price?

What is the current Woolworths (ASX:WOW) dividend payout ratio?

3 strong ASX growth shares for investors to buy in December

2 high-growth ASX shares profiting from the e-commerce boom

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!